{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ipilimumab&page=26", "query": { "intervention": "ipilimumab", "page": 26 }, "page_size": 10 }, "pagination": { "page": 26, "page_size": 10, "total_count": 640, "total_pages": 64, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ipilimumab&page=27&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ipilimumab&page=25&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-28T23:24:12.351Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07770100", "title": "Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer", "Non-Small Cell Lung Cancer", "Cervical Cancer", "Esophageal Cancer", "Gastric Cancer (GC)" ], "interventions": [ { "name": "Stereotactic Body Radiation Therapy (SBRT)", "type": "RADIATION" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Mark Bernard", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 35, "start_date": "2026-09-09", "completion_date": "2040-02-28", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-28T23:24:12.351Z", "location_count": 1, "location_summary": "Lexington, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT07770100" }, { "nct_id": "NCT04088500", "title": "A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2020-09-03", "completion_date": "2021-11-15", "has_results": true, "last_update_posted_date": "2023-01-10", "last_synced_at": "2026-10-28T23:24:12.351Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04088500" }, { "nct_id": "NCT03104439", "title": "Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Microsatellite Stable Colorectal Cancer", "Pancreatic Cancer", "MSI High Colorectal Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2017-05-10", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-10-28T23:24:12.351Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03104439" }, { "nct_id": "NCT01750580", "title": "Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "CANCER, NOS" ], "interventions": [ { "name": "Lirilumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2012-12", "completion_date": "2015-04", "has_results": false, "last_update_posted_date": "2015-07-22", "last_synced_at": "2026-10-28T23:24:12.351Z", "location_count": 6, "location_summary": "Tampa, Florida • Boston, Massachusetts • Minneapolis, Minnesota + 3 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01750580" }, { "nct_id": "NCT03101566", "title": "Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Biliary Tract Neoplasms" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2017-09-08", "completion_date": "2021-06-07", "has_results": true, "last_update_posted_date": "2022-10-28", "last_synced_at": "2026-10-28T23:24:12.351Z", "location_count": 7, "location_summary": "Atlanta, Georgia • Chicago, Illinois • Ann Arbor, Michigan + 4 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03101566" }, { "nct_id": "NCT06362369", "title": "A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer", "Advanced Solid Tumor", "Melanoma", "Metastasis", "Pleural Mesothelioma", "Renal Cell Carcinoma", "MSI-High", "Mismatch Repair Deficiency", "Colorectal Cancer", "Hepatocellular Carcinoma", "Hepatocellular Cancer", "Renal Cell Cancer", "Kidney Cancer", "Skin Cancer", "Non Small Cell Lung Cancer", "NSCLC", "Anaplastic Lymphoma Kinase Genomic Tumor Aberrations", "ALK Genomic Tumor Aberrations" ], "interventions": [ { "name": "Alintegimod", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "7 Hills Pharma, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 126, "start_date": "2024-08-23", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-10-28T23:24:12.351Z", "location_count": 5, "location_summary": "Aurora, Colorado • Lake Mary, Florida • Lebanon, New Hampshire + 2 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Lake Mary", "state": "Florida" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06362369" }, { "nct_id": "NCT02477826", "title": "An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2747, "start_date": "2015-08-05", "completion_date": "2024-10-25", "has_results": true, "last_update_posted_date": "2025-10-30", "last_synced_at": "2026-10-28T23:24:12.351Z", "location_count": 25, "location_summary": "Mobile, Alabama • San Francisco, California • New Haven, Connecticut + 19 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Marietta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02477826" }, { "nct_id": "NCT00113984", "title": "Vaccine and Antibody Treatment of Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "PROSTVAC-V/TRICOM", "type": "BIOLOGICAL" }, { "name": "PROSTVAC-F/TRICOM", "type": "BIOLOGICAL" }, { "name": "MDX-010", "type": "DRUG" }, { "name": "Sargramostim", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "MALE", "summary": "18 Years to 85 Years · Male only" }, "enrollment_count": 30, "start_date": "2005-06-08", "completion_date": "2011-12-01", "has_results": false, "last_update_posted_date": "2019-12-16", "last_synced_at": "2026-10-28T23:24:12.351Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00113984" }, { "nct_id": "NCT00289640", "title": "Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "ipilimumab (MDX-010, BMS-734016)", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 210, "start_date": "2006-04", "completion_date": "2007-07", "has_results": false, "last_update_posted_date": "2010-03-02", "last_synced_at": "2026-10-28T23:24:12.351Z", "location_count": 25, "location_summary": "Tucson, Arizona • Laverne, California • San Diego, California + 21 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Laverne", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00289640" }, { "nct_id": "NCT01672450", "title": "A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Intratumoral Ipilimumab and Interleukin-2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2012-09", "completion_date": "2014-08", "has_results": false, "last_update_posted_date": "2015-07-08", "last_synced_at": "2026-10-28T23:24:12.351Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01672450" } ] }